Disease Interception at the Point of Care
Interfacing MedTech & HealthTech to prevent diabetic vision loss
Our turnkey retinal screening solutions allow primary care physicians, endocrinologists and other clinical care professionals to better evaluate and manage patients living with diabetes. We help close the existing diabetic retinopathy (DR) screening gap to alleviate preventable vision loss.
What is the DR screening gap?
Vitazi exists at the interface of MedTech (data + AI) and HealthTech (teleretinal), promising to develop next-gen tools for early disease interception.
Our Solutions
Closing the DR screening gap
HealthTech
Vitazi-MD™ is a comprehensive turnkey teleretinal solution for diabetic retinopathy screening that eliminates the need for retinal dilation and specialized training. Any clinical staff member can conduct the test in under two minutes. Scans are reviewed by an off-site, board-certified ophthalmologist, and results are returned promptly. With no upfront costs and seamless workflow integration, Vitazi-MD was designed by physicians to improve HEDIS measures, increase revenue, and help prevent vision loss in diabetic patients.
MedTech
Vitazi-DR™ (AI) is currently in a US clinical trial and available now in Mexico. It offers the same complimentary turnkey solution for diabetic retinopathy screening as Vitazi-MD. However, AI autonomously reads the scans and returns in real-time.
